Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1629
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18383256 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | Non-Final OA | The Regents Of the University of California |
| 17634420 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | Final Rejection | The Regents of the University of California |
| 17727519 | Method of Treating Colorectal Cancers Using a PKC Inhibitor | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 17936179 | 23-O-ACETYLALISOL B AS A NOVEL THERAPEUTIC AGENT FOR CORONAVIRUS INDUCED SEVERE ACUTE RESPIRATORY SYNDROME | Final Rejection | The University of Hong Kong |
| 18784718 | OPHTHALMIC COMPOSITION | Non-Final OA | Sydnexis, Inc. |
| 17894884 | OPHTHALMIC COMPOSITION | Final Rejection | Sydnexis, Inc. |
| 17757609 | METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES | Final Rejection | Rutgers, The State University of New Jersey |
| 18735095 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Non-Final OA | ELEVATEBIO TECHNOLOGIES, INC. |
| 18221295 | INDOMETHACIN PHARMACEUTICAL COMPOSITION | Non-Final OA | FULTON MEDICINALI S.P.A. |
| 17765934 | PHARMACEUTICAL COMPOSITION COMPRISING ENZALUTAMIDE | Non-Final OA | Synthon B.V. |
| 17613467 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | Final Rejection | The Schepens Eye Research Institute, Inc. |
| 18037123 | COMBINATION THERAPY FOR THE TREATMENT OF A LIVER DISEASE | Final Rejection | INVENTIVA |
| 18295125 | MAGNETIC RESONANCE SPECTROSCOPY TO CALIBRATE AND SELECT DOSES, FORMULATIONS, AND DEVICES FOR INTRA-NASAL ADMINISTRATION OF N-ACETYLCYSTEINE | Final Rejection | Neuronasal, Inc. |
| 18125474 | COMPOSITIONS AND METHODS FOR REDUCING GREENHOUSE GAS | Final Rejection | Rumin8 Pty Ltd |
| 17985253 | BUPRENORPHINE DOSING REGIMENS | Non-Final OA | Indivior UK Limited |
| 17981673 | DRY POWDER INHALATION DRUG PRODUCTS EXHIBITING MOISTURE CONTROL PROPERTIES AND METHODS OF ADMINISTERING THE SAME | Non-Final OA | GLAXO GROUP LIMITED |
| 17519844 | STABLE CANNABINOID FORMULATIONS | Non-Final OA | Fresh Cut Development, LLC |
| 17367876 | STABLE CANNABINOID FORMULATIONS | Non-Final OA | Fresh Cut Development LLC |
| 17601148 | USE OF GINKGO TERPENE LACTONE IN PREPARING DRUG FOR PREVENTING AND/OR TREATING GUILLAIN-BARRE-STROHL SYNDROME | Non-Final OA | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. |
| 17333525 | PRODUCT AND METHOD FOR TREATING DIARRHEA | Non-Final OA | Maregade RX, LLC |
| 17252481 | PLASMALOGEN-CONTAINING COMPOSITION | Final Rejection | MARUDAI FOOD CO., LTD. |
| 15777385 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING FATTY PANCREAS OR AMELIORATING PANCREAS DISEASES CAUSED BY FATTY PANCREAS, DIABETES MELLITUS OR OTHER RELATED DISORDERS | Final Rejection | Jacob Biotechnology Co., Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy